We are live on ! Find out more
RARE icon

Ultragenyx Pharmaceutical

306 hedge funds and large institutions have $2.91B invested in Ultragenyx Pharmaceutical in 2025 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 132 increasing their positions, 91 reducing their positions, and 56 closing their positions.

New
Increased
Maintained
Reduced
Closed

160% more call options, than puts

Call options by funds: $88.2M | Put options by funds: $33.9M

45% more repeat investments, than reductions

Existing positions increased: 132 | Existing positions reduced: 91

5% more capital inflows, than outflows

Capital inflows: $686M | Capital outflows: $652M

0.7% more ownership

Funds ownership: 99.58% → 100.27% (+0.7%)

2% less first-time investments, than exits

New positions opened: 55 | Existing positions closed: 56

1% less funds holding

Funds holding: 310 → 306 (-4)

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
306
Holders Change
-4
Holders Change %
-1.29%
% of All Funds
3.99%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.05%
New
55
Increased
132
Reduced
91
Closed
56
Calls
$88.2M
Puts
$33.9M
Net Calls
+$54.3M
Net Calls Change
-$6.56M

RARE Hedge Fund Activity: Q3 2025 in Review

306 of the 7,661 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q3 2025, worth a combined $2.91B — down 15% from $3.42B a quarter earlier.

Sellers outnumbered buyers: 56 funds closed out of RARE and 55 opened new positions — a net loss of 1 holder — while 91 trimmed existing stakes and 132 added.

The largest buyer was Fidelity Investments, adding an estimated $140M. The largest seller was Alkeon Capital Management, exiting entirely with an estimated $61.3M sold.

  • 306 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q3 2025, down from 310 in Q2 2025.
  • Funds reported $2.91B of Ultragenyx Pharmaceutical stock for Q3 2025, down 15% quarter-over-quarter.
  • 55 funds opened new Ultragenyx Pharmaceutical positions in Q3 2025 and 56 closed out, a net change of -1 holder.
  • The largest Ultragenyx Pharmaceutical buyer in Q3 2025 was Fidelity Investments, an estimated $140M added.
  • The largest Ultragenyx Pharmaceutical seller in Q3 2025 was Alkeon Capital Management, an estimated $61.3M sold.

Based on aggregated 13F filings for Q3 2025.